28.08.2026 – 13:56

ARD Das Erste

"hart aber fair" am Montag, 31. August 2026, 21:00 Uhr, live aus Berlin

Bild-Infos Download

München (ots)

Moderation: Louis Klamroth

Das Thema: Vor den Wahlen im Osten: Woher kommt der Frust im Land?

Die Gäste:

Jan "Monchi" Gorkow (Sänger der Band Feine Sahne Fischfilet und Beststeller-Autor "Jenseits der Brandmauer")

Nikolaus Blome (Politikchef RTL/ntv und Spiegel-Kolumnist)

Hedwig Richter (Professorin für Neuere und Neueste Geschichte an der Universität der Bundeswehr München)

Luca Piwodda (Partei des Fortschritts, PdF, ehrenamtlicher Bürgermeister von Gartz (Oder) in Brandenburg)

Carolin Matzko (Moderatorin und Autorin, setzt sich in ihrem Buch damit auseinander, dass ihr Vater AfD-Mitglied ist)

Paul Burkhardt (betreibt eine familiengeführte Straußenfarm in Thüringen)

Direkt nach der Doku "Land unter Druck - 50 Stimmen aus dem Volk": Wut, Frust und Enttäuschung - vielerorts ist das die Reaktion auf die Politik aus Berlin. 71 Prozent der Deutschen sagen, die Demokratie habe sich in den vergangenen zehn Jahren eher zum Schlechteren entwickelt. Werden die Landtagswahlen im Herbst zur Abrechnung mit den etablierten Parteien? Schützt die Brandmauer die Demokratie - oder verschärft sie die politische Spaltung? Was muss passieren, dass die Bürger wieder zuversichtlicher in die Zukunft blicken? Und wie kann es der Politik gelingen, den Menschen zu vermitteln, dass ihre Stimme zählt?

So ist "hart aber fair" für Interessierte erreichbar: X: @hartaberfair, E-Mail hartaberfair@wdr.de, Homepage: www.hartaberfair.de

Redaktion: Torsten Beermann (WDR)

Pressekontakt:

Dr. Lars Jacob,

ARD-Programmdirektion, Presse und Information

Tel.: 089/558944-898

E-Mail: lars.jacob@ard.de

Original-Content von: ARD Das Erste, übermittelt durch news aktuell

28.08.2026 – 13:56

MDR Mitteldeutscher Rundfunk

MDR und MDM präsentieren: „Key Frames – Neue Animationsfilme aus Mitteldeutschland“

Bild-Infos Download 2 weitere Medieninhalte

Leipzig (ots)

Mit dem Förderprogramm „Key Frames 2026“ haben der Mitteldeutsche Rundfunk (MDR) und die Mitteldeutsche Medienförderung (MDM) die Produktion von sieben kurzen Animationsfilmen aus Mitteldeutschland erfolgreich realisiert. Die Filme entstanden innerhalb weniger Monate und überzeugen durch künstlerische Qualität und innovative Erzählweisen. Die Ergebnisse können sich sehen lassen – abrufbar ab sofort in der ARD Mediathek.

„Key Frames 2026“ wurde ins Leben gerufen, um die kreative Stärke und Vielfalt mitteldeutscher Künstler und Produktionsfirmen sichtbar zu machen. Nun liegen die Ergebnisse vor: Sieben Kurzfilme, die aktuelle gesellschaftliche Themen aufgreifen und eindrucksvoll die Leistungsfähigkeit der Animationsszene in Sachsen, Sachsen-Anhalt und Thüringen unter Beweis stellen.

MDR-Programmdirektor Boris Lochthofen: „Mit ‚Key Frames‘ konnten wir Kreativen aus Sachsen, Sachsen-Anhalt und Thüringen die Möglichkeit geben, relevante Themen aus ihrer Perspektive zu erzählen. Entstanden ist ein außergewöhnlich vielfältiges Spektrum an Filmen mit eigenständigen künstlerischen Handschriften. Die Ergebnisse zeigen, welches kreative Potenzial in der mitteldeutschen Animationsszene steckt und wie wirkungsvoll Animation gesellschaftliche Themen verhandeln kann.“

MDM-Geschäftsführer André Naumann: „Mit ‚Key Frames‘ wollten wir dem animierten Kurzfilm als eigenständige Kunstform eine neue Plattform bieten und zeigen, was für eindrucksvolle und relevante Geschichten aus unserer Region kommen. Die Vielfalt und künstlerische Qualität der entstandenen Filme haben uns sehr beeindruckt. Umso mehr freuen wir uns, dass das für die ansässigen Produzenten und Kreativen wichtige Programm im kommenden Jahr fortgesetzt wird und damit auch weiterhin Raum für besondere Stoffe und künstlerische Handschriften schafft. Den Filmen wünschen wir nun eine gute Reise zu den Festivals und in die Auswertung – linear wie in den Mediatheken – und hoffen, dass sie ein möglichst großes Publikum erreichen.“

Das sind die neuen Animationsfilme aus Mitteldeutschland

„Das letzte Wort“

Die dreiteilige Mini-Serie setzt erzgebirgische Holzfiguren an einen Stammtisch, an dem kontroverse gesellschaftliche Themen diskutiert werden:

„Tischvorlage I: Von Zwangsgebühr und Staatsfunk“

Nussknacker schimpft über den Rundfunkbeitrag und die Öffentlich-Rechtlichen. Gleichzeitig zeigt sich, dass alle ihre Lieblingssendungen haben – von Arztserien über das Sandmännchen bis zu Tierdokumentationen.

„Tischvorlage II: Von Tannen und Palmen“

Hitzewelle am Stammtisch: Allen läuft das Harz aus den Holzporen, und Tanne kommt verspätet von der Baumpflege. Während die einen in den Erneuerbaren eine gute Brise sehen, sprechen andere von „Windrädern der Schande“.

„Tischvorlage III: Vom Menschen und seiner Heimat“

Am Stammtisch prallen die Meinungen aufeinander: Nussknacker sorgt sich um die Kontrolle der Zuwanderung, Engel sieht die Entwicklung kritisch, während Harlekin für gleiche Rechte eintritt.

Prominente sächsische Comedians wie Tom Pauls und Anna Mateur leihen den erzgebirgischen Figuren ihre markanten Stimmen. Produziert wurde die Mini-Serie von Balance Film aus Dresden unter der Regie von Ralf Kukula.

„Made in Triptis“

Einst ausgewandert aus Thüringen, wird ein Schiffbrüchiger auf einer tropischen Insel von seiner Vergangenheit eingeholt, als die Brandung eine Tasse mit dem bekannten Triptiser Zwiebelmuster anspült.

Ein Film von Letty Felgendreher und Michael Knoll, mit der Stimme von Ilka Teichmüller. Produziert von Traumhaus Studios aus Erfurt.

„Geschwister: Ein letzter Wunsch“

Deutschland 2066: Die schwerkranke Jessica will ihre beiden entfremdeten Kinder noch einmal zusammenführen. Sie haben sich politisch, gesellschaftlich und menschlich in entgegengesetzte Richtungen entwickelt…

In packend gezeichneten Bildfolgen entfalten Sandra Strauß und der Leipziger Zeichner Schwarwel zwei konträre Zukunftsentwürfe aus denselben biografischen Ursprüngen und erzählen so nicht nur von einer Familie, sondern auch von einem Land im Wandel.

„Meier-Schmidt passt sich an“

Meier-Schmidt liebt seine Routine, doch die Welt um ihn herum verändert sich rasant. Ein humorvoller Animationsfilm, der uns den eigenen inneren Wutbürger vor Augen führt.

Produziert von DenverMP aus Halle; ein Film von Theresa Strozyk.

„Sprechzeit“

In schwierigen Zeiten erzählen Menschen aus Ost und West von Ausgrenzung und Entfremdung.

Produziert von hug films aus Halle; ein Film von Alina Cyranek und Falk Schuster.

Alle sieben „Key Frames“-Filme stehen ab sofort in der ARD Mediathek zum Abruf bereit. Im MDR-Fernsehen feiern die Filme am 30. Oktober im Rahmen der MDR-Kurzfilmnacht ihre lineare Premiere.

Von „Fokus“ zu „Key Frames“

Mit „Key Frames 2026“ knüpfen MDR und MDM an ihr gemeinsames Förderprogramm „Fokus“ an, das im Herbst 2024 gestartet ist. Während „Fokus“ den Filmnachwuchs in Mitteldeutschland insgesamt stärkt, richtet sich „Key Frames“ gezielt an kurze Animationsformate aus der Region.

Weitere Informationen gibt es hier: „KEY FRAMES 2026“: MDR und MDM fördern kurze Animationsfilme aus Mitteldeutschland | Presseportal

Pressekontakt:

Mitteldeutscher Rundfunk (MDR), Kommunikations- und Mediendesk, Tel.: (0341) 3 00 64 55, E-Mail: kommunikation-desk@mdr.de

Mitteldeutsche Medienförderung (MDM), presse@mdm-online.de, Telefon: +49 341 26987-14/-23/-33

Original-Content von: MDR Mitteldeutscher Rundfunk, übermittelt durch news aktuell

GLP-1 Users Are Spending Nearly 4x More on Fitness Than Other Consumers, New Report Finds

NEWS PROVIDED BY

The Consumer Collective

Aug 28, 2026, 08:00 ET

SHARE THIS ARTICLE

The Consumer Collective's national study of 500 U.S. adults shows GLP-1 users spend $449 a month on fitness, against $120 for non-users

BROOKLYN, N.Y., Aug. 28, 2026 /PRNewswire/ -- The Consumer Collective, a consumer insights and advisory firm, today released How America Spends on Fitness, a field report on U.S. fitness and wellbeing spending, which includes a focused study on GLP-1 medication users.

The headline finding: consumers taking GLP-1 medications spend $449 a month on fitness across categories, compared to $120 a month for non-users

GLP-1 users are more likely to pay for a gym membership (81 percent, against 43 percent of non-users) and spend more on personal training, supplements, and recovery. They also report walking more, doing more cardio, and eating more protein. At the same time, they say they're eating out, snacking, and drinking alcohol less than before starting the medication. GLP-1 users also report spending more at the grocery store even as restaurant and snack spending declines, pointing to a shift toward higher-quality food rather than simply eating less.

Clothing is a related spending driver: 63.4 percent of GLP-1 users report buying new clothes due to weight changes, and more than two-thirds have dropped at least two sizes.

25 percent of consumers surveyed report having taken a GLP-1 medication at some point, and 15 percent are currently taking one. Weight loss is the primary reason cited (61.8 percent), followed by diabetes and prediabetes management.

Beyond GLP-1 use, the report finds that health motivations are outpacing appearance-driven ones across the board. 70 percent of consumers say their focus on health is higher than it was a year ago, and sleep (87 percent) and mental wellbeing (86 percent) now rank above physical fitness (68 percent) and healthy eating (66 percent) as top consumer priorities.

Millennials lead both trends, spending $345 a month on fitness — the highest of any generation — and reporting the highest GLP-1 usage rate, at 29 percent.

"Fitness is one of the most important categories to consumers right now, but it's also an area where they tighten spending when things get tough. This report identifies shifting consumer habits and bright spots where spending is likely to remain fairly steady." Allison Collins, cofounder, The Consumer Collective

Methodology: The Consumer Collective fielded this survey online in July 2026 among a national sample of 500 U.S. adults ages 18–64, examining fitness, wellbeing, and GLP-1 medication habits. Figures are stratified to U.S. census demographics (age, gender, and region) unless otherwise noted. GLP-1 findings are based on a subsample of 123 users and 377 non-users.

About the report: How America Spends on Fitness is available now as a 20-page instant download at theconsumercollective.co. The report covers fitness motivation, spending by category, the GLP-1 effect on lifestyle and spending, and brand implications across the fitness, apparel, and wellness categories.

About The Consumer Collective

The Consumer Collective is a consumer insights and strategy advisory firm helping brands, founders, investors and technology companies navigate a rapidly changing consumer landscape. We connect the dots between how people live, think and spend and what those shifts mean for business. Our work brings together original consumer research, market intelligence, trend forecasting and deep sector expertise to identify emerging opportunities and separate lasting shifts from passing signals. From beauty and wellness to fashion, food, retail and technology, we help clients understand what is changing, decide where to focus and turn consumer insight into clear, actionable business strategy. Founded by Allison Collins and Jessica Ramírez, The Consumer Collective also publishes Inside The Collective, a paid weekly newsletter.

Media Contact

The Consumer Collective, info@theconsumercollective.co

SOURCE The Consumer Collective

21%

more press release views with 

Request a Demo

HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation USA - English

NEWS PROVIDED BY

Harvest Integrated Research Organization (HiRO)

Aug 28, 2026, 08:00 ET

SHARE THIS ARTICLE

Memorandum of Understanding establishes a framework for joint development of clinical trial simulation capabilities

The partnership unites global clinical operations excellence with advanced digital twin technology, delivering simulation-first drug development to biotech sponsors navigating an era of compressed timelines and escalating trial costs.

SOMERSET, N.J., Aug. 28, 2026 /PRNewswire/ -- At a time when biopharma R&D productivity is declining and the cost of bringing a single drug to market exceeds $2.6 billion, two companies are converging capabilities to change how clinical trials are designed, sized, and executed.

L-R: Karen Chu, CEO & Founder, HiRO; Shirley Wen, Founder, Differentia Biotech

Harvest Integrated Research Organization (HiRO), a full-service global clinical research organization (CRO), and Differentia Biotech Ltd. ("Differentia"), a pioneer in knowledge-empowered modeling and simulation for drug development, today announced a Memorandum of Understanding (MOU) establishing a strategic collaboration between the two companies. The agreement was formalized at HiRO's office, marking a new step in both organizations' efforts to bring more integrated, data-driven solutions to biopharmaceutical sponsors worldwide.

Under the MOU, HiRO and Differentia will pursue collaboration across two major areas, which address the pain points of biotech companies: joint exploration and development of clinical trial simulation models that combine HiRO's global clinical operations, data science, and real-world data expertise with Differentia's AI-powered digital twin and modeling and simulation platforms; and the development of new product offerings and commercial solutions built on those combined simulation capabilities.

The clinical trial simulation collaboration sits at the center of the partnership. By pairing HiRO's operational experience running trials across oncology, rare disease, cell and gene therapy, radiopharmaceuticals, and other complex indications with Differentia's modeling and simulation platforms, the collaboration leverages simulation-informed approaches to support smarter trial design, more efficient patient selection, potential reduction in the number of subjects needed, and better-informed sponsor decision-making earlier in development.

The collaboration reflects a shared view that sponsors increasingly benefit from pairing disciplined clinical trial execution with advanced modeling and simulation, helping to inform smarter trial design, manage risk, and support timelines across complex therapeutic areas.

Chief Executive Officer and Founder of HiRO, Karen Chu said, "Drug developers don't just need faster trials, they need smarter ones. Differentia's modeling and simulation expertise complements the operational discipline HiRO brings to every study, and this collaboration lets us explore how those strengths work together for the clients we both serve. We are aiming to support our biotech clients in better decision-making."

Founder of Differentia, Shirley Wen said, "As biopharma R&D productivity continues to decline, clinical development has become an increasingly significant source of cost, time, and risk. As FDA and global regulators increasingly embrace model-informed drug development, the industry must move from 'test in humans first' toward 'simulate first, then test in humans.' Together with HiRO's clinical development expertise, we aim to improve clinical success, reduce trial size, and accelerate time to market—ultimately creating greater value and ROI for every asset."

Chief Executive Officer and Co-Founder of Differentia, Kas Subramanian said, "By fusing advanced AI and biosimulations with HiRO's industry-leading clinical research expertise, we are creating high-fidelity digital twins that will fundamentally alter the drug development paradigm, allowing biotech pioneers to de-risk assets in a virtual environment and run the most efficient trials."

HiRO and Differentia expect to share additional details on specific collaborative initiatives as the partnership progresses.

About HiRO

Harvest Integrated Research Organization (HiRO) is a full-service global CRO delivering end-to-end clinical trial services across oncology, rare diseases, dermatology, metabolic disease, and specialized modalities including cell and gene therapy and radiopharmaceuticals. With more than 30 years of collective experience serving small, mid-size, and large biotech and pharma clients, over 500 professionals, and 1,600 trials delivered across 85 countries, HiRO combines global reach with regionally informed execution across North America, Europe, APAC, and ANZ. Learn more at www.harvestiro.com.

About Differentia Biotech

Differentia Bio is a San Francisco-based technology company building the AI-powered digital twin simulation and decision intelligence platform for drug R&D and life sciences. Combining AI with quantitative biosciences, Differentia enables life science decision makers to simulate critical decisions before committing real-world time, capital, and patients. Its validated, regulatory-ready simulation capabilities help biopharma decision makers to optimize development, accelerate regulatory submissions, and improve the value of their assets and portfolios. For more information, visit www.differentiabio.com.

Media Contacts

HiRO Marketing - info@harvestiro.com 

21%

more press release views with 

Request a Demo

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers

NEWS PROVIDED BY

Formosa Pharmaceuticals Inc.,

Aug 28, 2026, 08:03 ET

SHARE THIS ARTICLE

TSY-110 is positioned to become the first biosimilar alternative to Roche's Kadcyla® (ado-trastuzumab emtansine) in major regulated markets.

TAIPEI, Aug. 28, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced the submission of a Clinical Trial Application (CTA) to European regulatory authorities to conduct a pivotal clinical trial for TSY-110. TSY-110 is a biosimilar candidate referencing Roche's antibody-drug conjugate (ADC) Kadcyla® (ado-trastuzumab emtansine), indicated for HER2-positive metastatic and early-stage breast cancer.

Designed following regulatory guidance from both US and EU authorities, the upcoming trial will evaluate the safety, tolerability, pharmacokinetics, and immunogenicity profile of TSY-110 compared with the reference product. This milestone advances Formosa Pharmaceuticals' and EirGenix's shared goal of providing cost-effective biosimilar ADC treatments to patients across regulated global markets.

"Filing this CTA marks a significant achievement for Formosa Pharmaceuticals and underscores our strategic alliance with EirGenix," said Erick Co, Ph.D., President and Chief Executive Officer of Formosa Pharmaceuticals. "Antibody-drug conjugates have established themselves as mainstays in oncology, including HER2-positive breast cancer care, but patient access remains constrained by high treatment costs. Advancing TSY-110 into clinical evaluation is a momentous step toward fulfilling our goal of delivering world-class, accessible ADC options to oncologists and patients."

About TSY-110

TSY-110, also designated as EG12043, is an antibody-drug conjugate (ADC) biosimilar co-developed by Formosa Pharmaceuticals and EirGenix, Inc. (TWSE: 6589). The conjugate links HER2 monoclonal antibody, trastuzumab, with a cytotoxic payload (mertansine) to selectively eradicate HER2-overexpressing cancer cells while minimizing systemic toxicity. Comprehensive preclinical assessments demonstrate high biosimilarity, drug-antibody ratio (DAR) consistency, and comparable plasma kinetics to the reference product.

About HER2-Positive Breast Cancer Market

HER2-positive breast cancer accounts for a significant portion of all breast cancer diagnoses globally. Approximately 2.4 million breast cancer cases were diagnosed in 2024, with HER2+ disease affecting roughly 360,000 to 480,000 of these patients based on the standard 15–20% prevalence rate. HER2-targeted therapies continue to be a prominent tool in modern oncological care. Kadcyla®, approved by the FDA in 2013, generated approximately $2.5 billion in global sales in 2025.

About Formosa Pharmaceuticals, Inc.

Formosa Pharmaceuticals, Inc. (TWSE: 6838) is a Taiwan-based biopharmaceutical company focused on the development and commercialization of novel therapeutics in ophthalmology and oncology. The company leverages its proprietary APNT® nanoparticle formulation platform to optimize drug solubility and bioavailability. Formosa's pipeline includes FDA-approved APP13007 for post-surgical ocular inflammation and pain, alongside a robust portfolio of biosimilar and novel oncology assets. For more information, please visit www.formosapharma.com.

About EirGenix, Inc.

EirGenix Inc. (TWSE: 6589) operates on a dual business model combining CDMO with Product Development to fully leverage its cGMP manufacturing facilities and highly qualified technical staff. The company's core competitiveness stems from its dual technical capabilities in both mammalian cell line development and microbial fermentation, paired with comprehensive expertise across R&D, manufacturing, and analytics. Through a vertically integrated operational model, EirGenix maintains strict quality control and cost management and is Taiwan's largest biologics CDMO. For more information, please visit www.eirgenix.com.

SOURCE Formosa Pharmaceuticals Inc.,

21%

more press release views with 

Request a Demo

Virginia Cancer Specialists Welcomes Kai-Li Liang, MD, Expanding Access to Innovative Cancer Research Across the Mid-Atlantic

NEWS PROVIDED BY

Virginia Cancer Specialists

Aug 28, 2026, 08:04 ET

SHARE THIS ARTICLE

FAIRFAX, Va., Aug. 28, 2026 /PRNewswire/ -- Virginia Cancer Specialists, ranked #1 practice in Virginia for cancer care and across all medical specialties by Castle Connolly, is pleased to welcome Kai-Li Liang, MD. Dr. Liang is a board certified medical oncologist and clinical investigator whose expertise will further strengthen one of the region's most advanced and comprehensive cancer research programs.

Virginia Cancer Specialists welcomes Kai-Li Liang, MD, a board-certified medical oncologist and clinical investigator whose expertise will further strengthen one of the region’s most advanced and comprehensive cancer research programs.

Dr. Liang completed fellowship training in Medical Oncology at Johns Hopkins University School of Medicine after serving as Chief Resident and completing his residency in Internal Medicine at Johns Hopkins Bayview Medical Center. Dr. Liang earned his medical degree from Stony Brook University School of Medicine and his bachelor's degree in microbiology from the University of Maryland.

Dr. Liang joins Virginia Cancer Specialists at a pivotal time of growth for the practice's research and clinical trials program. With the largest community-based oncology clinical trials portfolio in the Mid-Atlantic region, Virginia Cancer Specialists continues to expand patient access to groundbreaking therapies. Dr. Liang's arrival enhances Virginia Cancer Specialists' ability to bring next-generation therapies to patients closer to home through participation in leading national and international clinical trials.

"Virginia Cancer Specialists has long been recognized as a leader in community-based cancer research, and we are thrilled to welcome Dr. Liang to our team," said Alex Spira MD, PhD, FACP, FASCO, Co-Director of the Virginia Cancer Specialists Research Institute and a nationally recognized clinical investigator. "His passion for advancing cancer treatment through clinical research aligns perfectly with our mission to bring the most innovative therapies directly to patients. As we continue expanding our research platform, Dr. Liang will play an important role in helping us accelerate access to the latest treatment opportunities throughout the region."

Virginia Cancer Specialists has been at the forefront of research advancement for decades, providing patients with access to clinical trials that may not otherwise be available in the community setting. The practice collaborates with leading pharmaceutical companies, cooperative research groups, and academic institutions to evaluate emerging therapies across a broad spectrum of cancer types.

"I'm excited to be joining the team at Virginia Cancer Specialists and to help bring next generation cancer therapies to patients," said Dr. Liang. "Early-phase clinical research is advancing how we treat cancer and I look forward to providing meaningful new options for patients."

In addition to expanding the research program, Dr. Liang will provide comprehensive cancer care while contributing to the development and execution of clinical studies designed to improve outcomes and quality of life for patients facing cancer.

With 10 locations across Northern Virginia, Virginia Cancer Specialists remains committed to delivering world-class cancer care through a combination of compassionate treatment, multidisciplinary expertise, and a robust research infrastructure that continues to shape the future of oncology.

About Virginia Cancer Specialists

Virginia Cancer Specialists, the largest private cancer practice in Northern Virginia, has been recognized as the #1 physician practice in Virginia in cancer care and across all medical specialties for 3 years running (2024-2026), as recognized by Castle Connolly Top Doctors. It features a world-class treatment team offering access to the most current treatment protocols fighting cancer and blood diseases. It's also home to the Virginia Cancer Specialists Research Institute and the largest clinical trials portfolio in the Mid-Atlantic – including a dedicated research facility for Phase I clinical trials and later-stage trials through a joint venture with Fairfax's NEXT Oncology. The practice offers medical oncology, radiation oncology, musculoskeletal tumor surgery, breast surgery, thoracic surgery, genetic counseling, support cancer care, financial counseling, onsite laboratory, onsite pharmacy, language services, telehealth, nurse advice line, and much more. Virginia Cancer Specialists is part of The US Oncology Network. This collaboration unites the practice with more than 600 sites of care across 31 states, 2,700 affiliated physicians, and research and data from thousands of patients with cancer in clinical trials across the country. Through its collaboration with Sarah Cannon Research Institute, Virginia Cancer Specialists offers access to a comprehensive menu of clinical studies and has contributed to pivotal research that has led to the approval of new cancer therapies. For more information about The US Oncology Network, which is supported by McKesson, a trusted name and global leader in healthcare for over 180 years, visit USOncology.com. For more information about Virginia Cancer Specialists, visit: VirginiaCancerSpecialists.com

Media Contact

Jean Dzierzak

Jean.Dzierzak@USOncology.com

703-963-5770

SOURCE Virginia Cancer Specialists

21%

more press release views with 

Request a Demo

Freedom Home Care Expands Beyond North Shore With New Huntley Office

NEWS PROVIDED BY

Freedom Home Care

Aug 28, 2026, 08:10 ET

SHARE THIS ARTICLE

The new location extends Freedom Home Care's private-pay home care services into McHenry and Kane counties for the first time.

HUNTLEY, Ill., Aug. 28, 2026 /PRNewswire/ -- Freedom Home Care, a private-pay home care provider and member of the PurposeCare family of companies, marked the opening of its first location outside the North Shore suburbs with a ribbon-cutting ceremony August 13. The company has operated in the North Shore for more than 28 years.

At a Glance:

New office: 12151 Regency Parkway, Suite 12169, Huntley, Illinois 60142

Ribbon-cutting took place: August 13, 2026

New office will focus on community programs, including Meaningful Mondays, launching September 2026

Newly reached service area: McHenry and Kane counties, including Huntley, Algonquin, and surrounding suburbs

The new location brings Freedom Home Care's services within reach of families in Huntley, Algonquin, and surrounding suburbs. Services available at the office include personal home care, outpatient services, and specialized support programs such as transportation and post-surgery assistance.

For Operations Manager Sarah Moore, the ribbon-cutting was the start of something bigger. Moore said she sees a broader role for the Huntley office within the community, built on education, connection, and partnership with the professionals and families who serve older adults in the area.

"We want the Huntley office to be more than a place people call when they need home care," Moore said. "We want to be a resource for the community. A place that brings older adults, caregivers, families, and professionals together through education, support, and meaningful connections."

The office is already building on that vision with new community programming. Living With Freedom, a series for older adults and caregivers that combines education, connection, and activities, opens Friday, August 28, with an Aromatherapy and Healthy Aging session from 10 to 11:30 a.m. The session includes an interactive aromatherapy experience and the chance for participants to make a custom scented lotion to take home.

Starting in September, the office will also launch Meaningful Mondays, a recurring series bringing local professionals together for networking and education on issues affecting older adults and the people who care for them.

Representatives from the Huntley Area Chamber of Commerce, the Algonquin/Lake in the Hills Chamber of Commerce, and the Village of Huntley joined healthcare and senior-service professionals, community partners, and Freedom Home Care team members at the ribbon-cutting.

Local businesses Blessed Little Kitchen, Brunch Cafe-Huntley, and Elle's Deli and Bagels also supported the celebration.

To learn more about Freedom Home Care's Huntley office and its upcoming community programs, visit freedomhomecare.net.

About Freedom Home Care

Freedom Home Care is a private-pay home care organization serving the Chicago metropolitan area. A member of the PurposeCare family of companies, Freedom Home Care provides personalized, concierge-level care for individuals who want trusted, flexible support at home. 

Media Contact:

Tyana Smith

Director of Marketing & Communications, PurposeCare

Tyana.Smith@purposecare.com

SOURCE Freedom Home Care

21%

more press release views with 

Request a Demo

GeeLark Expands Its AIGC Suite and Opens AI Content Creation to Free Users

NEWS PROVIDED BY

GeeLark

Aug 28, 2026, 08:15 ET

SHARE THIS ARTICLE

SINGAPORE, Aug. 28, 2026 /PRNewswire/ -- GeeLark today announced a major expansion of its AIGC capabilities, introducing new AI models and editing tools for social media content creation. Previously available only to paid users, GeeLark AIGC can now also be used on the free plan.

The update gives more social media managers access to AI content creation within the same platform they use for cloud phones, account management, and automation. It reflects GeeLark's broader strategy to bring content production and social media operations into one connected workspace.

GeeLark announces the expansion of its AIGC capabilities with new models like Seedance 2.5 now available on all plans including free users

More Models for Different Creative Needs

GeeLark now supports a broad selection of video generation models, including Seedance 2.5, Seedance 2.0, Seedance 2.0 Fast, Seedance 1.5 Pro, Seedance 1.0 Pro Fast, Kling 3.0, Kling 2.5, Veo 3.1, and Hailuo 2.3.

For image generation, users can choose from GPT Image 2, Kling 3.0, Nano Banana Pro, Seedream 5.0 Lite, and Seedream 4.0.

Instead of relying on a single model, SMM teams can choose different options based on creative style, output quality, generation speed, and campaign requirements. This provides greater flexibility when creating content for multiple accounts, platforms, and markets.

GeeLark also offers AI editing tools for slicing content, removing watermarks, and generating smart captions. These capabilities help teams prepare content for social media without moving every step between separate tools.

Bringing AIGC to Free Users

In previous versions, GeeLark's AIGC capabilities were limited to paid users. With the Aug. 27 update, free users can also access AIGC and explore its supported generation and editing tools.

Opening AIGC to the free plan lowers the barrier for individual creators and smaller teams that want to test AI-assisted content workflows before scaling their operations.

This expansion also reflects how GeeLark views AI: not as a premium add-on isolated from the rest of the platform, but as an increasingly important part of everyday social media work.

Built Around the Daily Work of SMM Teams

Through conversations with social media professionals at industry events and online, GeeLark found that many potential users were surprised to learn that AIGC was already built into the platform. Their reaction highlighted a common problem in today's social media technology stack.

SMM teams often use one group of tools to generate content, another to edit it, and separate platforms to manage accounts and execute campaigns. Each additional tool creates more subscriptions, file transfers, logins, and handoffs.

"Social media managers do not need AI as an isolated novelty. They need it to fit naturally into the work they already do," said Dominic, CEO of GeeLark. "By opening AIGC to free users and expanding our model selection, we are making AI content creation more accessible and more closely connected to real social media workflows."

From Content Generation to AI-Powered Operations

Generative AI has made content creation faster, but producing an image or video is only one part of a campaign. Teams still need to prepare content, manage accounts, work across platforms, and carry out repetitive operational tasks.

GeeLark is working to connect these stages more closely. AIGC supports the creative side of the workflow, while cloud phones and automation support the operational side of mobile-first social media management.

This positions GeeLark beyond a standalone AI generator. The company is building an integrated platform where teams can create content, prepare assets, manage operating environments, and scale social media workflows from one place.

As AI becomes more deeply embedded in marketing, its greatest value will not come from generation alone. It will come from connecting creative intelligence with the infrastructure needed to turn content into action.

SOURCE GeeLark

21%

more press release views with 

Request a Demo

James Malcolm Band's "Is It Never Too Late" Named Finalist in American Songwriter's Road Ready Talent Contest

NEWS PROVIDED BY

Settle Down Productions, LLC

Aug 28, 2026, 08:15 ET

SHARE THIS ARTICLE

South Florida band advances from the Semi-Finals as additional national recognition and new Fort Lauderdale performances add to a growing year

DAVIE, Fla., Aug. 28, 2026 /PRNewswire/ -- James Malcolm Band's "Is It Never Too Late" has been named a Finalist in American Songwriter's 3rd Annual Road Ready Talent Contest, advancing the South Florida-based band from an earlier Semi-Finalist round and putting it one step away from a potential live performance in Nashville.

American Songwriter announced the Finalists on Aug. 27. From the finalist field, the publication will next select three artists to perform live in Nashville in October 2026.

Malcolm Philip Flavell is the lead singer, co-founder, songwriter, and creative force behind the James Malcolm Band, named in tribute to his late father. Rooted in Fort Lauderdale, Florida, Malcolm writes honest songs about resilience, hope, relationships, second chances, and everyday life. With a distinctive voice and heartfelt storytelling, he and the band deliver an authentic American roots sound captured on their debut album, Never Too Late.

"Is It Never Too Late" was written and composed by Jason Milgram, Malcolm Flavell and Marc Loren. The Finalist selection gives both the song and James Malcolm Band national recognition as the band continues to develop its audience, recorded catalog and live presence.

"This is the kind of recognition that means a lot because it starts with the song," said Jason Milgram of Settle Down Productions. "We're proud of how far James Malcolm Band has come, but seeing 'Is It Never Too Late' advance from the Semi-Finals to the Finals makes this especially rewarding. Now we're hoping the band gets the opportunity to take that next step and perform it in Nashville."

For Malcolm Flavell, the recognition is also about seeing a song the band believes in reach listeners beyond its existing audience.

"You put a lot of yourself into a song and then hope it connects with somebody when you finally let it go," said Malcolm Flavell of James Malcolm Band. "To have 'Is It Never Too Late' reach the Finals with American Songwriter is something we're genuinely proud of. We're grateful to everyone who has listened, shared the music and come out to see us. Getting the chance to play this song in Nashville would be a pretty special next chapter."

A Second 2026 Finalist Recognition

The American Songwriter announcement comes as James Malcolm Band is also receiving recognition for its music video "Knock On Marble," which has been named a 2026 Finalist in the Music Video category of the Unsigned Only Music Awards.

The video is also eligible for Fandemonium, Unsigned Only's fan-voted award. Fans can vote once per day through Aug. 28, selecting the James Malcolm Band's "Knock On Marble."

The two Finalist selections give James Malcolm Band recognition for both its songwriting and visual work during the same period.

Fort Lauderdale Performances Continue This Fall

The national contest recognition arrives alongside an expanding live schedule in South Florida.

James Malcolm Band performed its first Fort Lauderdale concert in December 2025, followed by its second in July 2026. The band has since been invited to perform at a special Dolly Parton tribute on Sept. 7 at Savor Cinema in Fort Lauderdale.

James Malcolm Band will then return to Savor Cinema for its third Fort Lauderdale concert on Nov. 13, 2026.

The progression from its first local concert less than a year ago to multiple finalist recognitions and additional Fort Lauderdale appearances reflects a growing body of work for the band as Settle Down Productions continues to develop its recorded and live presence.

About James Malcolm Band

James Malcolm Band is a South Florida-based band represented by Settle Down Productions, LLC. The band releases original music and is building its audience through recorded releases and live performances. In 2026, James Malcolm Band earned Finalist recognition in American Songwriter's 3rd Annual Road Ready Talent Contest for "Is It Never Too Late" and in the Music Video category of the Unsigned Only Music Awards for "Knock On Marble."

Music, videos, social channels and additional information are available at:

https://linktr.ee/JamesMalcolmBand

About Settle Down Productions, LLC

Settle Down Productions, LLC is an independent music label based in Davie, Florida. The label works with its artists on music production, releases, promotion, audience development and live performance opportunities, with a focus on supporting their long-term career development.

SOURCE Settle Down Productions, LLC

21%

more press release views with 

Request a Demo

SuperX Secures 128 Units of B300 AI Server Purchase Order from Ezisight, Marking Its Official Entry into the Australian Market

NEWS PROVIDED BY

SuperX AI Technology Limited

Aug 28, 2026, 08:18 ET

SHARE THIS ARTICLE

SINGAPORE, Aug. 28, 2026 /PRNewswire/ -- SuperX AI Technology Limited (NASDAQ: SUPX, "SuperX" or the "Company"), a Nasdaq‑listed full‑stack AI infrastructure solutions provider, today announced that its subsidiary SuperX Microinference Pte Ltd ("Microinference") has signed an equipment and services supply agreement and has received the initial purchase order under the agreement from Australian compute service provider Ezisight Australia Pty Ltd. ("Ezisight"), trading under Ultimate AI Datacentre. The order covers the supply of 128 units of B300 AI server clusters. This long-term cooperation and initial order mark a substantive business breakthrough for SuperX in the Australian market and represents another key milestone in the Company's Asia‑Pacific business expansion.

Pursuant to the terms of the purchase order, the B300 AI servers are scheduled for delivery in the fourth quarter of 2026 and will be deployed in local Australian data centers to expand Ezisight's domestic GPU compute resource pool, supporting growing local workloads for large‑model training and AI inference.

B300 Compute Deployment in Australia: Long-Term Cooperation Bolsters SuperX's Next-Generation AI Compute Footprint

With the widespread adoption of generative AI and large‑model applications, global AI infrastructure is undergoing a continuous cycle of capacity expansion and upgrading. The Asia‑Pacific region, as a high‑growth hub for the AI industry, has seen sustained demand for server products featuring high compute density and high reliability. This long-term equipment and services cooperation together with the initial B300 server cluster order further validates SuperX's ability to keep pace with next‑generation GPU technology iterations and rapidly commercialize its products.

Australia's AI industry is in a phase of rapid development, with domestic enterprises and research institutions facing a widening gap in high‑performance GPU compute capacity. The B300 servers to be delivered under this long-term framework and initial order are expected to significantly enhance Ezisight's compute supply capacity, enabling it to address diverse local AI compute requirements and contribute to the development of Australia's domestic AI compute ecosystem.

Australia as A Key Strategic Market for SuperX's Asia‑Pacific Expansion

Australia is a priority market in SuperX's global expansion strategy for the Asia‑Pacific region. Driven by the robust growth of the domestic AI industry, market demand for stable and elastically scalable AI infrastructure continues to rise. Concurrently, Australian authorities have introduced multiple policies guiding data center operators toward greener and more sustainable operations, creating significant market demand for compute infrastructure that combines high performance with environmental sustainability.

This long-term supply agreement together with the initial purchase order from Ezisight serves as a landmark project for SuperX's official entry into the Australian market. Through fulfilling this project, the Company will accumulate hands‑on experience in project implementation, supply chain coordination, and localized service delivery in Australia. Beyond expanding SuperX's customer base across Oceania, this order lays a solid foundation for the Company's deeper penetration into the Australian and surrounding regional AI infrastructure markets.

Going forward, SuperX intends to further strengthen its presence in Australia and other high‑potential Asia‑Pacific markets by providing full‑stack AI infrastructure products and solutions to meet the region's growing industrial compute demand. Based on this cooperation, both parties will jointly assess potential opportunities for future capacity expansion procurement and localized technical collaboration.

Evolving from standalone server hardware toward full‑stack AI infrastructure, SuperX continues to enhance its comprehensive capabilities spanning hardware products, liquid‑cooling and power‑supply solutions, and end‑to‑end data center delivery. The Company will continue to track technological advances in next‑generation GPUs and AI computing, iterate its products and solutions, and improve its overseas localized delivery and service systems. Through these efforts, SuperX aims to capture long‑term growth opportunities arising from AI infrastructure build‑outs in Asia‑Pacific and globally, and to further expand its market presence in the global AI compute industrial chain.

About SuperX AI Technology Limited (NASDAQ: SUPX)

SuperX AI Technology Limited is an AI infrastructure solutions provider, offering a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, 800 Volts Direct Current (800VDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. Headquartered in Singapore, the Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments. For more information, please visit www.superx.sg

About Ezisight Australia Pty Ltd.

Ezisight is an Australian‑based provider of green AI infrastructure and GPU‑as‑a‑Service. Trading as Ultimate AI Datacentre (www.ultimateaidc.net), it focused on building and operating modular edge supercomputing facilities, it delivers compute for large‑model training and inference to local enterprises and research institutions with behind‑the‑meter renewable‑energy and water‑positive cooling technology. Its business footprint covers Asia‑Pacific and Africa, with a proven track‑record in AI‑compute project delivery and industry‑academia collaboration.

Safe Harbor Statement

This press release may contain forward‑looking statements. In addition, we or our representatives may from time to time make forward‑looking statements orally or in writing. These forward‑looking statements are based on our expectations and projections about future events derived from information currently available to us. You can identify forward‑looking statements by their non‑historical nature, particularly by terms such as "may", "should", "expects", "anticipates", "estimates", "believes", "plans", "projects", "potential", or "hopes" and their negatives or similar expressions. In evaluating these forward‑looking statements, you should consider various factors including: our ability to redirect the Company; our ability to keep pace with new technologies and changing market demands; and the competitive environment of our business. These and other factors may cause actual results to differ materially from any forward‑looking statements.

Forward‑looking statements are only predictions. Readers are cautioned not to place undue reliance on these forward‑looking statements. The forward‑looking events discussed in this press release (including delivery timelines, capacity, order value, counterparty performance risks, potential future capacity expansion and business‑collaboration opportunities, and other statements made by us or our representatives from time to time) may not occur, and actual circumstances and results may differ materially. Actual delivery timelines and values for AI servers may vary subject to customer data‑center readiness and supply‑chain conditions. We undertake no obligation to publicly update or revise any forward‑looking statements whether as a result of new information, future events or otherwise.

Follow our social media:

X.com: https://x.com/SUPERX_AI_

LinkedIn: https://www.linkedin.com/company/superx-ai

Facebook: https://www.facebook.com/people/Super-X-AI-Technology-Limited/61578918040072/#

SOURCE SuperX AI Technology Limited

21%

more press release views with 

Request a Demo